Biomarkers for tuberculosis detection, progression, and treatment optimisation: an umbrella review of systematic reviews
The Lancet Microbe · 2026-11 · 101580
DOI: 10.1016/j.lanmic.2026.101580 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026-11. Verfasst von Tiffeney Mann und 14 weiteren Autor:innen. Beteiligte Einrichtung: University of Warwick, Coventry, UK. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, NIHR Biomedical Research Centre Imperial, Wellcome Trust.
Abstract (Originalsprache)
Background
Biomarkers have been widely proposed as having potential to improve tuberculosis (TB) detection, prediction of progression, and treatment monitoring, but evidence is fragmented and it is unclear which biomarkers have the strongest evidence base. We undertook an umbrella review to synthesise this evidence.
Methods
This umbrella review (PROSPERO CRD420251230142) evaluated systematic reviews of biomarkers for three broad TB use-cases: detection of TB disease, prediction of progression to TB disease, and TB treatment monitoring and optimisation. We searched MEDLINE, Web of Science, Global Index Medicus and Cochrane Library for systematic reviews of host- or pathogen-derived biomarkers from January 2018 and appraised review quality using AMSTAR-2. For each biomarker class and use case we summarised the technology readiness, strength of evidence, diagnostic accuracy, extent of independent validation, operational characteristics, and unmet need addressed. We synthesised evidence for each biomarker class qualitatively and quantitatively, against a pre-specified biomarker prioritisation framework.
Findings
Forty-five systematic reviews met inclusion criteria: 39 on TB detection, 7 on progression and 6 on treatment monitoring. Nine classes of host- or pathogen-based biomarkers were identified, most commonly host protein, host transcriptomic and host miRNA. For TB detection, evidence was strongest for host protein, host transcriptomic, and pathogen antigen classes, while the immune phenotype, exhaled breath and pathogen DNA/RNA classes were earlier in development, lacking independent validation. Across use cases, estimates of diagnostic accuracy varied widely and were often lower in higher quality studies with clinically relevant populations. In high-quality studies no biomarkers consistently met WHO target product profile thresholds. For TB progression, the strongest evidence was for host transcriptomic, which predicted the short-term risk of TB progression but showed modest performance over longer follow-up intervals. For TB treatment monitoring, evidence to predict clinical outcomes is limited across all classes.
Interpretation
Many systematic reviews have been published describing numerous TB biomarkers, especially for the TB detection use case. Robust validation of candidate biomarkers in clinically relevant populations is lacking for many classes. Further prospective head-to-head validation studies are needed to determine which biomarkers have meaningful potential to improve individual and public health outcomes.
Autor:innen und Institutionen
- University of Warwick, Coventry, UK.
- UCL Respiratory, Division of Medicine, University College London, London, UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.
- UCL Respiratory, Division of Medicine, University College London, London, UK.
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
- University of Sydney Vietnam Institute, Ho Chi Minh City, Viet Nam.
- Institute of Health Informatics, University College London, London, UK; Department of Infectious Diseases, Luigi Sacco Hospital, Regional Center for Infectious Diseases (CEREMI), Lombardy Region, Milan, Italy.
Förderung
- National Institute for Health and Care Research
- NIHR Biomedical Research Centre Imperial
- Wellcome Trust
- Canadian Institutes of Health Research
Zitieren
APA
Mann, T., Greenan-Barrett, J., Wright, S., Steward, E., Nguyen, T. M., Aung, K. M., Duong, L., Fama, F., Garg, C., de Wilton, A., Engel, N., Yerlikaya, S., Gupta-Wright, A., MacLean, E. L., & Gupta, R. K. (2026). Biomarkers for tuberculosis detection, progression, and treatment optimisation: an umbrella review of systematic reviews. The Lancet Microbe, 101580. https://doi.org/10.1016/j.lanmic.2026.101580
Vancouver
Mann T, Greenan-Barrett J, Wright S, Steward E, Nguyen TM, Aung KM, et al. Biomarkers for tuberculosis detection, progression, and treatment optimisation: an umbrella review of systematic reviews. The Lancet Microbe. 2026:101580. doi:10.1016/j.lanmic.2026.101580
BibTeX
@article{Mann2026,
author = {Mann, Tiffeney and Greenan-Barrett, James and Wright, Sacha and Steward, Ellen and Nguyen, Thi Mai and Aung, Khay Mar and Duong, Linh and Fama, Federico and Garg, Chhavi and de Wilton, Angus and Engel, Nora and Yerlikaya, Seda and Gupta-Wright, Ankur and MacLean, Emily L-H and Gupta, Rishi K},
title = {Biomarkers for tuberculosis detection, progression, and treatment optimisation: an umbrella review of systematic reviews},
journal = {The Lancet Microbe},
year = {2026},
pages = {101580},
doi = {10.1016/j.lanmic.2026.101580}
}
EUVIMED